Clinical Trial Update: AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AGEN1423 and Botensilimab with or without chemotherapy in advanced pancreatic ductal adenocarcinoma; currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• AGEN1423 (AGEN1423)
• Botensilimab (botensilimab)

Snippet

Sponsor: Bruno Bockorny | Conditions: Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING